Juan Calle Cano, MD
Nephrology · Cleveland, OHNPI 1477783470
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.6%), speaking fees and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Travere Therapeutics, Inc. at 48.7% of the total.
Across 34 payments — averaging $49.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$813
- Boston Scientific$276
- Novo Nordisk$134
- Penumbra, Inc.$112
- Otsuka America Pharmaceutical, Inc.$107
- Novartis$53
- plus $172 from 5 others
Across 6 payments — averaging $3177.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$19K
What the payments were for
- Speaking & faculty fees$75045%
- Food & beverage$89554%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 12 | $813 |
| Boston Scientific | 3 | $276 |
| Novo Nordisk | 2 | $134 |
| Penumbra, Inc. | 1 | $112 |
| Otsuka America Pharmaceutical, Inc. | 5 | $107 |
| Novartis | 3 | $53 |
| Calliditas Therapeutics US Inc. | 2 | $50 |
| Amgen(2 entities) | 2 | $45 |
| Medtronic | 2 | $40 |
| Bayer | 1 | $21 |
| Fresenius USA Marketing, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (815) Thiola$750
- SpyGlass Discover$125
- Indigo System$112
- Rivfloza$111
How this compares
$1,668 in reported general payments places this provider in the 60th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 70 | $6,915 |
| InvokanaCanagliflozin | 12 | $6,901 |
| Chlorthalidone | 69 | $1,023 |
| Potassium Chloride | 17 | $718 |
| Allopurinol | 42 | $435 |
| Losartan Potassium | 49 | $315 |
| Torsemide | 14 | $288 |
| Spironolactone | 22 | $261 |
| Omega-3 Acid Ethyl Esters | 12 | $180 |
| Carvedilol | 21 | $169 |
| Hydralazine Hcl | 15 | $86 |
| Lisinopril | 33 | $84 |
| Amlodipine Besylate | 19 | $83 |
| Hydrochlorothiazide | 11 | $76 |
| Minoxidil | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Cleveland
- Georges NakhoulCleveland$255K
- Sankar NavaneethanCleveland$253K
- Sevag DemirjianCleveland$158K
- Elias BassilCleveland$80K
- Ali MehdiCleveland$76K
- Amitkumar PatelCleveland$70K
- Emilio PoggioCleveland$41K
- Corey CavanaughCleveland$35K
- James SimonCleveland$29K
- Ziad ZakyCleveland$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.